MARKET

KNSA

KNSA

Kiniksa Pharmaceuticals International, plc
NASDAQ
43.09
+0.51
+1.20%
After Hours: 43.09 0 0.00% 16:53 02/06 EST
OPEN
42.77
PREV CLOSE
42.58
HIGH
43.74
LOW
42.69
VOLUME
312.75K
TURNOVER
--
52 WEEK HIGH
45.50
52 WEEK LOW
18.12
MARKET CAP
3.27B
P/E (TTM)
96.12
1D
5D
1M
3M
1Y
5Y
1D
Director Barry D. Quart Reports Disposal of Common Shares in Kiniksa Pharmaceuticals International plc
Reuters · 3d ago
Assessing Kiniksa Pharmaceuticals (KNSA) Valuation After Strong Earnings Growth And Accelerating Sales
Simply Wall St · 5d ago
Weekly Report: what happened at KNSA last week (0126-0130)?
Weekly Report · 6d ago
Citi Sticks to Its Buy Rating for Kiniksa Pharmaceuticals (KNSA)
TipRanks · 01/30 11:26
Does Rapid Earnings Growth and Upbeat Analyst Sentiment Change The Bull Case For Kiniksa (KNSA)?
Simply Wall St · 01/30 05:28
TD Cowen Remains a Buy on Kiniksa Pharmaceuticals (KNSA)
TipRanks · 01/29 12:26
Weekly Report: what happened at KNSA last week (0119-0123)?
Weekly Report · 01/26 09:38
Kiniksa: Arcalyst Is The Engine, But KPL-387 Is The Accelerator
Seeking Alpha · 01/24 05:40
More
About KNSA
Kiniksa Pharmaceuticals International, plc is a biopharmaceutical company focused on discovering, acquiring, developing and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications. Its portfolio of assets is based on strong biologic rationale or validated mechanisms and offers the potential for differentiation. Its ARCALYST is used for the treatment of recurrent pericarditis and reduces the risk of recurrence in adults and children 12 years and older. ARCALYST is also approved for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome, and the maintenance of remission in Deficiency of Interleukin-1 Receptor Antagonist. Its other portfolio includes KPL-387, KPL-1161, Abiprubart, and Mavrilimumab. Mavrilimumab is an investigational monoclonal antibody inhibitor targeting granulocyte-macrophage colony stimulating factor receptor alpha.

Webull offers Kiniksa Pharmaceuticals Internationl PLC stock information, including NASDAQ: KNSA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KNSA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading KNSA stock methods without spending real money on the virtual paper trading platform.